IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results
IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.
![IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results](https://www.psuconnect.in/sdsdsd/IOL_Chemicals_and_Pharmaceuticals.jpg)
IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results
NEW DELHI- IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.
Q4 FY23 Financial Highlights
· Total income for Q4 FY23 stood at Rs. 596 crore as against Rs. 530 crore in Q3 and Rs.579 crore YoY
· EBITDA for Q4 FY23 at Rs. 104 crore as compared to Rs. 50 crore in Q3 and Rs. 50 crore YoY
· Net profit for Q4 FY23 at Rs. 65 crore as compared to Rs. 24 crore in Q3 FY23 and Rs. 28 crore YoY
FY23 Financial Highlights
· Total income for FY23 stood at Rs. 2,243 crore as compared to Rs. 2,216 crore in FY22
· EBITDA for FY23 at Rs. 252 crore as compared to Rs. 288 crore in FY22
· Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Read Also : IndusInd Bank Q1 FY25 results, net profit at 2% YoYQ4FY23 Financial Highlights
(Rs in Crore)
Particulars |
Quarterly |
Yearly |
||||||
Q4FY23 |
Q3FY23 |
% QoQ |
Q4FY22 |
% YoY |
FY23 |
FY22 |
% YoY |
|
Total Income |
595.9 |
530.1 |
12.4% |
579.4 |
2.9% |
2242.7 |
2,216.1 |
1.2% |
EBITDA |
104.5 |
49.7 |
110.3% |
50.0 |
108.8% |
252.1 |
288.3 |
-12.6% |
EBITDA Margin (%) |
17.5% |
9.4% |
á 810 bps |
8.6% |
á 890 bps |
11.2% |
13.0% |
â 180 bps |
PAT |
65.3 |
24.2 |
169.8% |
27.7 |
135.2% |
140.0 |
165.7 |
-15.5% |
PAT Margin (%) |
11.0% |
4.6% |
á 640 bps |
4.8% |
á 620 bps |
6.2% |
7.5% |
â 130 bps |
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalization and margin improvement.
With significant operational, technical, and commercial efficiencies, improved market combination, and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory
Read Also : India assumes the Chair of Asian Disaster Preparedness CentreNews Must Read
- Karnataka Bank Announced record Q1 Net Profit at Rs. 400.33 CR
- NTPC, BHEL shares soar higher amid JV announcement in Budget 2024
- BEL signs tripartite MoU for manufacture of indigenised ammunition
- Goa Shipyard Limited launched first indigenous P1135.6 Frigate
- Chandan Sinha appointed as Non-Executive Part Time Chairman of RBL Bank
- OIL and Dolphin Drilling signs contract for hiring of Blackford Dolphin
- Cmde D.K. Murali, IN (Retd.) Joins as CMD of BECIL
- Samir Chandra Saxena Appointed as Director (Market Operation) of GRID-INDIA
- MOIL CMD bags Title 'CEO of the Year'
- ONGC sign MoU with GSI to advance geothermal exploration in Ladakh